Results 41 to 50 of about 113,982,624 (231)

Renal Outcome of Immunoglobulin A Nephropathy With Mild Proteinuria [PDF]

, 2003
We determined the natural history of immunoglobulin A nephropathy (IgAN) among patients who presented with mild proteinuria (0.2 to 0.4 g/day), and factors associated with development of adverse clinical events, defined as proteinuria 竕ｧ 1.0g/day, blood ...
Miyazaki, Masanobu, Taguchi, Takashi, Tadokoro, Masato, Kohno, Shigeru, Harada, Takashi, Suyama, Naofumi, Horita, Yoshio, Taura, Kouichi, Ozono, Yoshiyuki   +8 more
core  

Emerging therapies in immunoglobulin A nephropathy [PDF]

Nephrology, 2015
AbstractDespite advances in our understanding of immunoglobulin A nephropathy (IgAN) over the past decade, there are currently no specific therapies capable of targeting key pathways involved in the pathogenesis of the disease. Recent studies have, however, provided new insights into important molecular pathways that are likely to be amenable to ...
See Cheng, Yeo, Adrian, Liew, Jonathan, Barratt   +2 more
openaire   +2 more sources

CASTOR1 regulates humoral immune responses and contributes to the pathogenesis of systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objectives CASTOR1 senses arginine and regulates mammalian target of rapamycin complex 1 (mTORC1), a central metabolic signaling molecule. This study aimed to elucidate the roles of CASTOR1 in humoral immune responses. Methods We analyzed human B cell transcriptomes from healthy controls and patients with systemic lupus erythematosus (SLE) via ...
Takeshi Kusuda, Toshihiko Komai, Takahiro Itamiya, Tatsuki Abe, Tomohisa Okamura, Keishi Fujio   +5 more
wiley   +1 more source

Correlation of arteriolar hyalinosis and clinicopathological features in patients with IgA nephropathy and hypertension

Di-san junyi daxue xuebao, 2022
Objective To explore the differences in clinical indicators and clinicopathological characteristics immunoglobulin A nephropathy (IgAN) patients with hypertension accompanied with arteriolar hyalinosis and those without.
SHEN Yunzhu, XIONG Jiachuan, ZHAO Jinghong   +2 more
doaj   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up

, 2006
In progressive immunoglobulin A nephropathy (IgAN), intravenous immunoglobulin (IVIg) treatment has been used to delay disease progression, but the long-term efficacy is largely unknown.
Müller, L von, Czock, David, Keller, Frieder, Sailer, Leif-Conradin, Czock, D, von Müller, Lutz, Karges, W, Aymanns, Christian, Rasche, F M, Rasche, Franz Maximilian, Lepper, P M, Karges, Wolfram, Sailer, L-C, Keller, F, Aymanns, C   +14 more
core   +1 more source

Use of antibiotics for the treatment of immunoglobulin a nephropathy

, 2019
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. IgA is mainly produced by the gut associated lymphoid tissue (GALT).
Gleeson, James, Monteiro, Renato, Berthelot, Laureline, Mkaddem, Sanae Ben, Chemouny, Jonathan, Lepage, Patricia   +5 more
core   +4 more sources

Pleomorphic presentations of IgA nephropathy - postrenal transplantation

Indian Journal of Transplantation, 2018
IgA nephropathy (IgAN) is a common cause of glomerulonephritis and end-stage renal disease. The recurrence of IgAN postrenal transplant is well documented.
Andrew Rajiv, Sampath Kumar Krishnaswamy, Shakti Kumar   +2 more
doaj   +1 more source

Prognostic value of the Oxford classification and the Oxford score in IgA nephropathy: A Tunisian study

Saudi Journal of Kidney Diseases and Transplantation, 2020
Immunoglobulin A nephropathy is the most common primary glomerular disease. The main challenge in this disease is the evaluation of prognostic factors for end-stage renal disease. The aim of our study was to describe the characteristics of immunoglobulin
Hela Jebali, Hiba Ghabi, Ikram Mami, Badr Ben Kaab, Lilia ben Fatma, Wided Smaoui, Slim Haouet, Hend Ben Mahjouba, Mohanad Hassan, Fethi Ben Hmida, Lamia Raies, Mohamed Karim Zouaghi   +11 more
doaj   +1 more source